PRECIPIO, INC.

Revenue reaches quarterly record as Precipio returns to positive Adjusted EBITDA and strengthens cash position NEW HAVEN, CT, Globenewswire – (Aug 14, 2026) – Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO), announces financial results for the second quarter that ended June 30, 2026. Below are some of the key financial performance metrics for the Company. [...] The post Precipio Announces Q2-2026 Financial Results appeared first on Precipio.

Conference Call will be held on August 17th, 2026, at 5:00 PM EST NEW HAVEN, CT, (July 31st, 2026) – Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO), will be hosting its Q2-2026 shareholder update call on August 17th, 2026, at 5:00 PM ET. The call will include remarks on the company’s current core businesses, as well as [...] The post Precipio Announces Q2-2026 Shareholder Update Call appeared first on Precipio.

NEW HAVEN, CT, (June 12th, 2026) – Management of specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO) is requesting that shareholders instruct their brokers to vote their shares immediately. Votes must be received by 11:59 p.m., Eastern Time, on June 14, 2026, to be voted at the Annual Meeting In order to ensure that there is a quorum required for the shareholders’ [...] The post Precipio is requesting Shareholders/Brokers vote today to avoid costly adjournment and rescheduling of Annual Shareholders Meeting appeared first on Precipio.

NEW HAVEN, CT, Globenewswire – (June 11, 2026) – Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO), announces that it will be presenting at the Planet MicroCap Las Vegas 2026 on Wednesday, June 17, 2026, at 9:00 AM (Local Time, 12:00pm EST) at the Bellagio Resort & Hotel. Ilan Danieli, CEO and Zaki Sabet, COO of [...] The post Precipio to Present at the Planet MicroCap Las Vegas appeared first on Precipio.

Stable revenue performance driven by timing dynamics; expanding product pipeline expected to drive second-half growth NEW HAVEN, CT, Globenewswire – (May 14, 2026) – Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO), announces financial results for the first quarter ended March 31, 2026. Below are some of the key financial performance metrics for the Company. Please [...] The post Precipio Announces Q1 2026 Financial Results appeared first on Precipio.

Share price increase from $6 to $30 triggers full vesting NEW HAVEN, CT, (May 13th, 2026) – Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO) announces that 2025 employee stock options granted to certain members of Precipio’s management team vested last week because the Company’s Common Stock price increased by more than 400% since the options were granted. [...] The post Management team’s 2025 market-based Options have vested appeared first on Precipio.

Conference Call will be held on May 18th, 2026, at 5:00 PM EST NEW HAVEN, CT, (May 6th, 2026) – Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO), will be hosting its Q1-2026 shareholder update call on May 18th, 2026, at 5:00 PM ET. The call will include remarks on the company’s current core businesses, as well as [...] The post Precipio Announces Q1-2026 Shareholder Update Call appeared first on Precipio.

Conference Call to be held on April 2nd, 2026 at 5:00 PM EST NEW HAVEN, CT, (March 12th, 2026) – Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO), will be hosting its Q4 and year end 2025 corporate update call on April 2nd, 2026 at 5:00 PM ET. The call will include updates on all of the company’s [...] The post Precipio Announces Q4 and year-end 2025 Shareholder Update Call appeared first on Precipio.

This is the only assay available on the market that delivers full quantification of all four clinically relevant BCR::ABL1 isoforms NEW HAVEN, CT, (March 10th, 2026) – Specialty cancer diagnostics company Precipio, Inc. (NASDAQ:  PRPO) has announced the publication¹ in the Journal of Clinical Pathology of a study conducted in collaboration with the Memorial Sloan-Kettering Cancer Center, demonstrating [...] The post Precipio Announces Publication of a Joint Study with Memorial Sloan-Kettering Cancer Center Highlighting Its Cutting-Edge Bloodhound BCR::ABL1 Assay appeared first on Precipio.

In Q4-2025 the Company generated ~$400K in Operating Cash Flow, and Adjusted EBITDA of close to $1M NEW HAVEN, CT, Globenewswire – (February 25, 2025) – Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO), announces some preliminary (unaudited) financials for Q4-2025 and for its fiscal year 2025. Below are some of the key financial performance metrics [...] The post Precipio 2025 (Unaudited) Revenues Grew to $24.0M, a 30% Increase Year-Over-Year appeared first on Precipio.